We are live on ! Find out more
BNTCW

Benitec Biopharma Limited

Delisted

BNTCW was delisted on the 14th of April, 2020.

1 hedge funds and large institutions have $4K invested in Benitec Biopharma Limited in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more capital invested

Capital invested by funds: $2K → $4K (+$2K)

50% less funds holding

Funds holding: 21 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1K
Name Holding Trade Value Shares
Change
Change in
Stake
CH
1
CVI Holdings
Delaware
$4K
SM
2
Sabby Management
Florida
-$1K -51,449 Closed

BNTCW Hedge Fund Activity: Q4 2019 in Review

1 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma Limited (BNTCW) for Q4 2019, worth a combined $4K — up 100% from $2K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BNTCW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $1K sold.

  • 1 institutional investor held Benitec Biopharma Limited (BNTCW) as of Q4 2019, down from 2 in Q3 2019.
  • Funds reported $4K of Benitec Biopharma Limited stock for Q4 2019, up 100% quarter-over-quarter.
  • 0 funds opened new Benitec Biopharma Limited positions in Q4 2019 and 1 closed out, a net change of -1 holder.
  • The largest Benitec Biopharma Limited seller in Q4 2019 was Sabby Management, an estimated $1K sold.

Based on aggregated 13F filings for Q4 2019.